KR890005056A - 피리딜에탄올아민, 이를 함유하는 약제학적 조성물 및 이의 제조방법 - Google Patents
피리딜에탄올아민, 이를 함유하는 약제학적 조성물 및 이의 제조방법 Download PDFInfo
- Publication number
- KR890005056A KR890005056A KR1019880011275A KR880011275A KR890005056A KR 890005056 A KR890005056 A KR 890005056A KR 1019880011275 A KR1019880011275 A KR 1019880011275A KR 880011275 A KR880011275 A KR 880011275A KR 890005056 A KR890005056 A KR 890005056A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- group
- addition salts
- acid addition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Hydrogenated Pyridines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- 하기 일반식(I)의 피리딜에탄올아민, 이의 광학이성체, 부분입체이성체 및 산 부가염.상기 식에서, R은 카복시메톡시, 카보메톡시메톡시, 에톡시 카보닐메톡시 또는 2-하이드록시에톡시 그룹을 나타낸다.
- 제1항에 있어서, N-[2-(4-(2-하이드록시에톡시)페닐)-1-메틸에틸]-2-하이드록시-2-(6-클로로-피리딘-2-일)에틸아민, 이의 광학이성체, 부분입체이성체 및 산부가염.
- 제1항 또는 제2항에 있어서, 무기 또는 유기산과 제1항 또는 제2항에서 청구된 화합물과의 생리학적으로 허용되는 염.
- 제1항 또는 제2항에서 청구한 화합물 또는 제3항에서 청구한 생리학적으로 허용되는 산 부가염을 임의로 하나 또는 그 이상의 불활성 담체 및/또는 희석제와 함께 함유하는 약제학적 조성물.
- 진성 당뇨병 및 비만증의 치료와 아테롬성 동맥경화증의 치료 및 예방에 적합한 약제학적 조성물을 제조하기 위한, 제1항 내지 제3항중 적어도 어느 한 항에서 청구한 화합물의 용도.
- 제1항 내지 제3항중 적어도 어느 한 항에서 청구한 화합물을 비-화학적 방법으로 하나 또는 그 이상의 불활성 담체 및/또는 희석제내로 혼입시킴을 특징으로 하여 제4항에서 청구한 약제학적 조성물을 제조하는 방법.
- (a)일반식(II)의 화합물을 일반식(III)의 화합물과 반응시키거나, (b) 일반식(V)의 아민을 사용하여 일반식(IV)의 카보닐 화합물을 환원적으로 아민화시키거나, c) 일반식(VI)의 화합물을 환원시키거나, d) 일반식(VII)의 화합물을 일반식(IX)의 화합물과 반응시키고[여기서, 반응 a) 내지 d)에서 반응성 그룹들은 반응후에 통상적인 방법으로 다시 제거할 수 있는 통상적인 보호그룹으로 반응동안에 보호할 수 있다]. 계속해서 경우에 따라, 이렇게 하여 수득한, R이 메톡시카보닐메틸 또는 에톡시카보닐메톡시 그룹을 나타내는 일반식(I)의 화합물을 가수분해시켜 R이 카복시메톡시 그룹을 나타내는 상응하는 일반식(I)의 화합물로 전환시키고/거나, 이렇게하여 수득한 일반식(I)의 화합물을 이의 광학이성체 및 부분입체이성체로 분할하고/하거나, 이렇게 하여 수득한 일반식(I)의 화합물을 이의 산 부가염, 특히 생리학적으로 허용되는 이의 산부가염으로 전환시킴을 특징으로하여 제1항 내지 제3항중 적어도 어느 한 항에서 청구한 피리딜에탄올아민을 제조하는 방법.상기식에서, Y1은 구조식의 그룹을 나타내고, Y2는 일반식(여기서, R은 제1항 또는 제2항에서 정의한 바와 같다)의 그룹을 나타내며, 그룹 Y1또는 Y2중의 하나는 반드시 수소원자를 나타내고, U는 일반식(여기서, R은 제1항 또는 제2항에서 정의한 바와 같다)의 그룹을 나타내며, Z1및 V는 함께 하나의 결합을 형성하거나, Z1은 친핵성 이탈그룹을 나타내고, V는 수소원자를 나타내며, R은 제1항 도는 제2항에서 정의한 바와 같고, R1은 카복시메틸, 메톡시카보닐메틸, 에톡시카보닐메틸 또는 2-하이드록시에틸그룹을 나타내며, Z2는 할로겐원자 또는 설포닐옥시그룹과 같은 친핵성 이탈그룹을 나타내거나 그룹 R1의 베타-수소 원자와 함께 산소원자를 나타낸다.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19873729284 DE3729284A1 (de) | 1987-09-02 | 1987-09-02 | Neue heteroarylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DEP3729284.6 | 1987-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR890005056A true KR890005056A (ko) | 1989-05-11 |
Family
ID=6335037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019880011275A KR890005056A (ko) | 1987-09-02 | 1988-09-01 | 피리딜에탄올아민, 이를 함유하는 약제학적 조성물 및 이의 제조방법 |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0305845B1 (ko) |
JP (1) | JPH0196172A (ko) |
KR (1) | KR890005056A (ko) |
AT (1) | ATE81851T1 (ko) |
AU (1) | AU617353B2 (ko) |
CA (1) | CA1331005C (ko) |
DE (2) | DE3729284A1 (ko) |
DK (1) | DK486988A (ko) |
FI (1) | FI884003A (ko) |
IL (1) | IL87620A0 (ko) |
NZ (1) | NZ226006A (ko) |
PT (1) | PT88392B (ko) |
ZA (1) | ZA886501B (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4918086A (en) * | 1987-08-07 | 1990-04-17 | Ciba-Geigy Corporation | 1-nitro-2,2-diaminoethylene derivatives |
DE4006794A1 (de) * | 1990-03-03 | 1991-09-05 | Bayer Ag | Verfahren zur herstellung von aminoethanolderivaten |
CN1297540C (zh) * | 2002-07-17 | 2007-01-31 | 力奇制药公司 | 用作胆固醇生物合成抑制剂的吡啶基乙醇(苯乙基)胺的衍生物、它们的制备方法和含有它们的药物组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3615293A1 (de) * | 1986-05-06 | 1987-11-12 | Bayer Ag | Verwendung von heteroarylethylaminen zur leistungsfoerderung bei tieren, heteroarylethylamine und verfahren zu ihrer herstellung |
CA1287061C (en) * | 1986-06-27 | 1991-07-30 | Roche Holding Ltd. | Pyridine ethanolamine derivatives |
DE3627663A1 (de) * | 1986-08-14 | 1988-03-03 | Bayer Ag | Heteroarylethylamine, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer bei tieren |
ES2021105B3 (es) * | 1987-03-07 | 1991-10-16 | Bayer Ag | Procedimiento para la obtencion de 5-amino-4,6-dihalogeno piridinas. |
-
1987
- 1987-09-02 DE DE19873729284 patent/DE3729284A1/de not_active Withdrawn
-
1988
- 1988-08-22 DE DE8888113612T patent/DE3875563D1/de not_active Expired - Fee Related
- 1988-08-22 AT AT88113612T patent/ATE81851T1/de not_active IP Right Cessation
- 1988-08-22 EP EP88113612A patent/EP0305845B1/de not_active Expired - Lifetime
- 1988-08-31 NZ NZ226006A patent/NZ226006A/en unknown
- 1988-08-31 IL IL87620A patent/IL87620A0/xx unknown
- 1988-08-31 CA CA000576154A patent/CA1331005C/en not_active Expired - Fee Related
- 1988-08-31 FI FI884003A patent/FI884003A/fi not_active Application Discontinuation
- 1988-09-01 JP JP63219623A patent/JPH0196172A/ja active Pending
- 1988-09-01 ZA ZA1988/06501A patent/ZA886501B/en unknown
- 1988-09-01 KR KR1019880011275A patent/KR890005056A/ko not_active Application Discontinuation
- 1988-09-01 AU AU21790/88A patent/AU617353B2/en not_active Ceased
- 1988-09-01 DK DK486988A patent/DK486988A/da not_active Application Discontinuation
- 1988-09-01 PT PT88392A patent/PT88392B/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JPH0196172A (ja) | 1989-04-14 |
EP0305845A1 (de) | 1989-03-08 |
ATE81851T1 (de) | 1992-11-15 |
CA1331005C (en) | 1994-07-26 |
FI884003A0 (fi) | 1988-08-31 |
ZA886501B (en) | 2008-05-30 |
PT88392B (pt) | 1992-10-30 |
DE3729284A1 (de) | 1989-03-23 |
DK486988A (da) | 1989-03-03 |
NZ226006A (en) | 1991-05-28 |
DK486988D0 (da) | 1988-09-01 |
EP0305845B1 (de) | 1992-10-28 |
DE3875563D1 (de) | 1992-12-03 |
FI884003A (fi) | 1989-03-03 |
PT88392A (pt) | 1989-07-31 |
IL87620A0 (en) | 1989-01-31 |
AU2179088A (en) | 1989-03-02 |
AU617353B2 (en) | 1991-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0024382B1 (en) | Piperidine derivatives, their preparation and pharmaceutical compositions containing them | |
RU2200161C2 (ru) | Новые производные азолидиндиона, способ их получения (варианты), фармацевтические композиции на их основе, способ предупреждения или лечения, способ снижения глюкозы и промежуточное соединение | |
EP0279281B1 (en) | Lipoxygenase inhibiting compounds | |
HU193161B (en) | Process for preparing new n-alkyl-norscopines | |
JPH08504819A (ja) | フロルフェニコール、チアンフェニコール、クロラムフェニコールおよびオキサゾリン中間体の不整製造方法 | |
US20090093650A1 (en) | Resolution of alpha-(phenoxy)phenylacetic acid derivatives with naphthyl-alkylamines | |
DK143128B (da) | Analogifremgan&smaade til fremstilling af 1-aryloxy-2-hydroxy-3-alkylaminopropaner eller deres fysiologisk acceptable syreadditionssalte | |
FR2744448A1 (fr) | Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments | |
US7714131B2 (en) | Process for the stereoselective preparation of (−)-halofenate and derivatives thereof | |
EP0494817B1 (fr) | Dérivés de benzisoxazole et de benzisothiazole, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
KR890005056A (ko) | 피리딜에탄올아민, 이를 함유하는 약제학적 조성물 및 이의 제조방법 | |
EP0348257A2 (fr) | Nouveaux dérivés d'(hétéro)aryl diazole, leur procédé de préparation et leur application en thérapeutique | |
US2430116A (en) | Alkamine esters of oxy substituted diarylhydroxyacetic acids | |
KR880006239A (ko) | 기라제 억제제, 그의 제조방법 및 용도 | |
JPH0542429B2 (ko) | ||
EP0005091B1 (fr) | Nouvelles pipérazines monosubstituées, leurs procédés de préparation et les compositions pharmaceutiques les renfermant | |
CH505072A (de) | Verfahren zur Herstellung von Sulfonylharnstoffderivaten | |
ES8105970A1 (es) | Procedimiento para preparar acidos metil aminoalcanoicos fluorados. | |
TW197412B (ko) | ||
CA1085841A (en) | Aryloxy proplamines, their preparation and use thereof | |
KR910002450A (ko) | 당뇨병 치료용 제약 조성물 | |
ES8106727A1 (es) | Procedimiento de preparacion de derivados 15-hidroxiimino-e-homoeburnanos,de sus sales de adicion acidas y de sus deri- vados opticamente activos | |
EP0287042B1 (en) | 2-sulphinyl-acetyl-1,3-thiazolidines, their preparation and pharmaceutical compositions | |
FR2529550A1 (fr) | Derives d'acide apovincaminique, procede pour leur preparation et compositions pharmaceutiques contenant ces derives | |
DE50211588D1 (de) | Verfahren zur kontinuierlichen Herstellung von substituierten Oxazolen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |